Indian drug maker Piramal Healthcare Ltd said reports about a potential sale of the company to GlaxoSmithKline Plc or Sanofi Aventis SA were 'unfounded.'
Glaxo and Sanofi have emerged as bidders for the Indian firm, with a sale price perhaps as high as $1.5 billion, a source familiar with the situation told Reuters on Friday.
"We would like to clarify that this is totally unfounded," the Indian firm said in a statement issued on Saturday.
"Piramal Healthcare continues to have a strong belief about the significant potential of our core businesses. Accordingly, we have invested in our sales force, built state-of-the-art facilities and continue to pursue acquisitions opportunistically," the company said.
The firm recently acquired select brands of India-based Khandelwal Labs, PlasmaSelect, and US-based RxElite Inc and is set to complete the acquisition of US-based Minrad International.
Piramal's business includes custom manufacturing, in which it helps formulate and package drugs for other firms on a contract basis, with operations in North America, Europe and Asia.
For the year ended March 2008, Piramal clocked revenue of about $590 million.